T cell engaging bispecific antibodiesMSLN490mesothelinpaclitaxelT cell engaging bispecific antibodies (TCBs) have recently become significant in cancer treatment. In this study we developed MSLN490, a novel TCB
Secondly, in addition to recruiting effector T cells, T-cell redirecting bispecific antibodies also recruit other immune cells, which may lead to drug resistance. ⑥ Infection. Infections are common in patients receiving bispecific antibody therapy, and combination therapy increases the risk of ...
[2]Pillarisetti K, Powers G, Luistro L, et al.Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393. [3]Smith, E., Olson, K., Haber, L. e...
Identifying a strategy with strong efficacy against non-inflamed tumours is vital in cancer immune therapy. ERY974 is a humanized IgG4 bispecific T cell-redirecting antibody that recognizes glypican-3 and CD3. Here we examine the combination effect of ER
Abbreviations: ADCC: Antibody-dependent cellular cytotoxicity; AlphaScreenTM: Amplified Luminescent Proximity Homogeneous Assay Screening; ANOVA: Analysis of variance; BiTE: bispecific T-cell engager; BSA: bovine serum albumin; BsAb: bispecific antibody; cFAE: controlled Fab-arm exchange; CDC: complement...
Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an “off-the-shelf” product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell ...
nature communications Article https://doi.org/10.1038/s41467-022-32952-3 Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours Received: 17 March 2021 Accepted: 25 August 2022 Check for updates Yuji Sano 1 , Yumiko ...
T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances Article 23 February 2019 Emerging immunological strategies: recent advances and future directions Article Open access 06 December 2021 References Abraham N, Miceli M, Parnes JR, Veilette A (1991) Enhancement of T-...
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cell
Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody recognizing glypican-3 and CD3, is in phase I clinical trials. After a first-in-human clinical trial of an anti-CD28 agonist monoclonal antibody resulting in severe life-threatening adverse events, the minimal anticipated ...